CD47 and lymphoma: CD20-CD47SL, a CD47xCD20 BsAb, was observed to selectively bind to dual antigen-expressing lymphoma cells in the presence of an “antigen sink” of RBCs and recapitulated the synergistic effects of anti-CD47 antibody and rituximab combinations in mouse models of NHL [10].